This technology features the novel Propionibacterium freudenreichii MJ2 strain isolated from raw milk, along with pharmaceutical compositions for preventing and treating metabolic diseases and food compositions for improving obesity-related metabolic disorders using this strain as an active ingredient. The strain inhibits fat accumulation and adipocyte differentiation, and suppresses increases in body weight, body fat, blood glucose, and plasma total cholesterol.
Obesity significantly increases the risk of metabolic diseases such as diabetes, hyperlipidemia, hypertension, and fatty liver. However, many commercially available anti-obesity drugs have had their approvals revoked due to side effects including psychiatric disorders, myocardial infarction, stroke, and gastrointestinal issues. While safe alternatives using probiotics have been researched, they have primarily focused on lactic acid bacteria and Bifidobacterium, leaving the anti-obesity efficacy of Propionibacterium freudenreichii—a GRAS strain used as a cheese starter—largely unexplored.
This technology utilizes the MJ2 strain, identified by the 16S rDNA sequence of SEQ ID NO: 1, to restore fasting blood glucose, blood lipids, insulin, and liver/adipose tissue fat accumulation elevated by a high-fat diet to normal levels, while also protecting liver function. It demonstrates superior activity compared to the existing anti-obesity strain Lactobacillus plantarum. Applicable to health functional foods for body fat reduction, probiotic ingredients for managing fatty liver and hyperglycemia, and as a starter for dairy products like fermented milk and cheese, it allows for the management of obesity and metabolic disorders without concerns regarding liver toxicity or bowel dysfunction, based on a strain with proven safety as a food ingredient.
N/A
